AB-FUBINACA 3-fluorobenzyl isomer

Cat. No.: HY-114880: Ficha de datos Instrucciones de manejo
FAQs
Technical Support

AB-FUBINACA 3-fluorobenzyl isomer is a synthetic cannabinoid that belongs to the indole derivatives and has a high affinity for the central CB1 receptors (K_i= 0.9 nM), exhibiting anticonvulsant activity.

Para uso exclusivo en investigación. No vendemos a pacientes.

AB-FUBINACA 3-fluorobenzyl isomer Estructura química

No. CAS : 1185282-19-2

Tamaño	Stock	Cantidad
1 mg	Obtener un presupuesto 3 - 4 Weeks 4 - 5 Weeks 5 - 6 Weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
5 mg	Obtener un presupuesto 3 - 4 Weeks 4 - 5 Weeks 5 - 6 Weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
10 mg	Obtener un presupuesto 3 - 4 Weeks 4 - 5 Weeks 5 - 6 Weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
50 mg	Obtener un presupuesto
100 mg	Obtener un presupuesto

Synthetic products have potential research and development risk.

or Consulta para venta a granel

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 1 Customer Validation

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas Cannabinoid Receptor:

Ver todas las isoformas

CB1 CB2

Actividad biológica
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn	AB-FUBINACA 3-fluorobenzyl isomer is a synthetic cannabinoid that belongs to the indole derivatives and has a high affinity for the central CB1 receptors (K_i= 0.9 nM), exhibiting anticonvulsant activity^[1].
Peso molecular	368.40
Fòrmula	C₂₀H₂₁FN₄O₂
No. CAS	1185282-19-2
SMILES	O=C(C1=NN(C2=C1C=CC=C2)CC3=CC(F)=CC=C3)N[C@@H](C(C)C)C(N)=O
Envío	Room temperature in continental US; may vary elsewhere.
Almacenamiento	Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación	Ficha de datos (273 KB) Instrucciones de manejo (2659 KB)
Referencias	[1]. Aliesha Griffin, et al. Phenotype-Based Screening of Synthetic Cannabinoids in a Dravet Syndrome Zebrafish Model. Front Pharmacol. 2020 Apr 24:11:464. [Content Brief]